(Reuters Health)—Patients who receive biologic infusions at home may have a higher risk of adverse events than those who receive the infusions at a health care facility, a new study suggests.1 Researchers examined administrative claims data on 57,220 adults who received a total of 752,150 biologic infusions for immune-mediated disease between 2007 and 2017. The…
Add-On Voclosporin Improves Outcomes in Lupus Nephritis
NEW YORK (Reuters Health)—Voclosporin (Lupkynis) in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study. “Lupus nephritis can be a devastating condition if not diagnosed and managed early. These data establish voclosporin as an…
Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar
Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.
The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab
As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.
Pegloticase Safe & Effective for Patients with Gout on Dialysis
Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.
More Info on the J&J COVID-19 Vaccine Thrombosis Scare
More than 7 million doses of the Johnson & Johnson single-dose vaccine have been administered in the U.S.1 On Apr. 23, the Centers for Disease Control & Prevention (CDC) and the U.S. Food & Drug Administration (FDA) recommended lifting the recommended pause on Johnson & Johnson COVID-19 vaccine use following a thorough safety review. 2…
Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?
A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…
COVID-19 Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab
FDA News Release—On April 16, saying that alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and…
ACR, Ophthalmologists & Dermatologists Issue Joint Hydroxychloroquine Statement
Since 1991, hydroxychloroquine (HCQ) has been a staple for the treatment of patients with systemic lupus erythematosus; it has been shown to improve survival, reduce cardiovascular risk, thrombosis and renal damage, delay or prevent lupus cerebritis and more. However, HCQ can potentially bind in the retinal pigment epithelium and cause degeneration of photoreceptors, leading to…
Cigna Offers Patients Financial Incentive to Switch Treatments
The ACR has sent a letter to Cigna expressing opposition to the initiative, which jeopardizes patients’ health, interferes with medical decision making, undermines the doctor-patient relationship and may disproportionately affect patients of lower socioeconomic status.
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 120
- Next Page »